skip to Main Content

ESG News Review 11 — 17 January 2014

  • 20 January 2014

Alstom appeared among the most praised companies last week, as it announced it would cease engaging sales consultants to ensure it “conducts business in a responsible way and strives to achieve the highest ethical standards”. Alstom is also calling for…


Pledge of $150m to fight neglected diseases

  • 14 October 2010

Six pharmaceutical companies and several governments have pledged more than $150m in medicines and funding over five years to tackle some of the most neglected diseases. The debilitating illnesses — including leprosy, lymphatic filariasis and sleeping sickness — affect 1bn…


The Humanitarian Sponsorship Charter

  • 15 September 2008

Sanofi-aventis selects humanitarian sponsorship actions on the basis of 6 main criteria: Consistency: Prioritize thematic actions: health - solidarity - childhood in the field of prevention, education, training, hygiene, access to care, combating exclusion, disability, children's traumas... Usefulness: Respond to…


Big drug companies raided in EU probe

  • 17 January 2008

European regulators raided some of the world's biggest pharmaceutical companies yesterday in an inquiry into whether they conspired to keep up the price of drugs after patents expired. Pfizer, GlaxoSmithKline, AstraZeneca and Sanofi-Aventis were among those that confirmed they had…


Innovation et philanthropie dopent le marché des vaccins

  • 8 January 2008

En 2007, le laboratoire américain Merck a supplanté Sanofi Aventis à  la tàªte du classement mondial des producteurs de vaccins. GlaxoSmithKline (GSK), qui talonnait Sanofi, se retrouve donc numéro trois. Sur les neuf premiers mois de 2007, Merck a réalisé…


The Burden of Innovation – Covalence Pharmaceutical Industry Report 2007

  • 29 August 2007

Pharmaceutical companies carry increasing ethical risks related to innovation, states a report released on 29 August 2007 by Geneva-based ethical reputation research firm Covalence, Covalence Pharmaceutical Industry Report 2007. These innovation-related risks deal with intellectual property rights, drug pricing, clinical…


The Ethically Challenged: How Pharma Fares

  • 31 May 2007

In these ethically challenging times, which drugmaker has its act together? Covalence, a research group based in Geneva that tracks ethical reputations, recently released its quarterly update in which various industrial sectors were examined. The firm compiles its rankings and…

Back To Top